Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.

Publication date: Jul 22, 2025

We evaluated the effectiveness of the Sinopharm coronavirus disease 2019 (COVID-19) vaccine, introduced in Mozambique, against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), prevalent from March 2022 to December 2023. A test-negative case-control study was nested in a community-based enhanced COVID-19 surveillance in seven healthcare facilities including mobile testing stations in the Dondo District, Mozambique, between March 2022 and December 2023. Participants were individuals aged ≥2 years with COVID-19-like symptoms for

Semantics

Original Article